🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Chuck Royce’s CMPX Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+285,988 Shares
Current Position
285,988 Shares
$1.54 M Value

Chuck Royce's CMPX Position Overview

Chuck Royce (via Royce & Associates Lp) currently holds 285,988 shares of Compass Therapeutics, Inc. (CMPX) worth $1.54 M, representing 0.02% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Chuck Royce has initiated a new position in CMPX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Chuck Royce's Compass Therapeutics (CMPX) Holding Value Over Time

Track share changes against reported price movement

Quarterly Compass Therapeutics (CMPX) Trades by Chuck Royce

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +285,988 New Buy 285,988 $5.37

Chuck Royce's Compass Therapeutics Investment FAQs

Chuck Royce first purchased Compass Therapeutics, Inc. (CMPX) in Q4 2025, acquiring 285,988 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Chuck Royce has held Compass Therapeutics, Inc. (CMPX) for 1 quarters since Q4 2025.

Chuck Royce's largest addition to Compass Therapeutics, Inc. (CMPX) was in Q4 2025, adding 285,988 shares worth $1.54 M.

According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 285,988 shares of Compass Therapeutics, Inc. (CMPX), valued at approximately $1.54 M.

As of the Q4 2025 filing, Compass Therapeutics, Inc. (CMPX) represents approximately 0.02% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.

Chuck Royce's peak holding in Compass Therapeutics, Inc. (CMPX) was 285,988 shares, as reported at the end of Q4 2025.